2010
Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors
Ellis M, Cassera M, Vetto J, Orloff S, Hansen P, Billingsley K. Surgical treatment of intrahepatic cholangiocarcinoma: outcomes and predictive factors. Hepato Pancreato Biliary 2010, 13: 59-63. PMID: 21159105, PMCID: PMC3019543, DOI: 10.1111/j.1477-2574.2010.00242.x.Peer-Reviewed Original ResearchConceptsOverall survival rateIntrahepatic cholangiocarcinomaR0 resectionSurgical treatmentR1/R2 resectionResectable intrahepatic cholangiocarcinomaPostoperative liver failureMainstay of treatmentOptimal patient selectionPostoperative complication rateKaplan-Meier methodCox hazard modelPreoperative hypoalbuminaemiaReplete patientsR2 resectionSurgical mortalityComplication rateSurgical resectionSurgical therapyWorse survivalClinicopathologic characteristicsLiver failureOperative detailsPrognostic factorsRecurrence outcomes
2006
Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors
Gupta M, Sheppard B, Corless C, MacDonell K, Blanke C, Billingsley K. Outcome Following Surgical Therapy for Gastrointestinal Stromal Tumors. Journal Of Gastrointestinal Surgery 2006, 10: 1099-1105. PMID: 16966028, DOI: 10.1016/j.gassur.2006.05.014.Peer-Reviewed Original ResearchConceptsGastrointestinal stromal tumorsMultivisceral resectionStromal tumorsMetastatic diseaseSurgical resectionImatinib mesylateDuodenal gastrointestinal stromal tumorKIT-positive gastrointestinal stromal tumoursCox proportional hazards modelPercent of patientsComplete surgical resectionKaplan-Meier methodLog-rank analysisPresence of metastasesLimits of resectionProportional hazards modelMitotic indexHigh mitotic indexActuarial survivalPostoperative survivalIncomplete resectionSurgical therapyComplete resectionImproved survivalIndependent predictors
2004
Racial Disparities in Rectal Cancer Treatment: A Population-Based Analysis
Morris A, Billingsley K, Baxter N, Baldwin L. Racial Disparities in Rectal Cancer Treatment: A Population-Based Analysis. JAMA Surgery 2004, 139: 151-155. PMID: 14769572, DOI: 10.1001/archsurg.139.2.151.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overBlack PeopleCohort StudiesColectomyConfidence IntervalsCross-Sectional StudiesFemaleHealth Care SurveysHumansIncidenceLogistic ModelsMaleMiddle AgedNeoplasm StagingOdds RatioPostoperative ComplicationsProbabilityRectal NeoplasmsRisk FactorsSEER ProgramSex FactorsSocioeconomic FactorsSurvival AnalysisUnited StatesWhite PeopleConceptsRectal cancer patientsRectal cancerCancer patientsRadiation therapyCross-sectional cohort studyRadiation treatmentRacial disparitiesEnd Results (SEER) databaseSphincter-sparing proceduresRectal cancer treatmentAdvanced disease stagePopulation-based dataDelivery of careSignificant racial disparitiesAdvanced diseaseAggressive screeningCohort studySurgical therapyPelvic cancerSurveillance EpidemiologyResults databaseTreatment disparitiesDisease stageMinority patientsSurgical care
2001
The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population
Billingsley K, Maynard C, Schwartz D, Dominitz J. The use of trimodality therapy for the treatment of operable esophageal carcinoma in the veteran population. Cancer 2001, 92: 1272-1280. PMID: 11571743, DOI: 10.1002/1097-0142(20010901)92:5<1272::aid-cncr1448>3.0.co;2-a.Peer-Reviewed Original ResearchConceptsOperable esophageal carcinomaTrimodality therapyEsophageal carcinomaPerioperative mortalityDistal esophageal tumorsOutpatient clinic filesOutcomes of patientsRetrospective cohort studyOverall perioperative mortalityFavorable prognostic factorPredictors of survivalAbsence of metastasesMain outcome measuresPatient Treatment FileRecord Locator SystemType of treatmentHealth care systemInduction chemoradiotherapyMidesophageal tumorsNeoadjuvant chemoradiotherapyCohort studyMedian survivalOverall survivalPatient ageSurgical therapy